Clinical trial
Aripiprazole in Adolescents With Schizophrenia
NCT00102063 · Otsuka Pharmaceutical Development & Commercialization, Inc., Industry · Completed
Key facts
| NCT number | NCT00102063 |
|---|---|
| Title | Aripiprazole in Adolescents With Schizophrenia |
| Official title | Aripiprazole in Adolescents With Schizophrenia |
| Acronym | APEX 239 |
| Lead sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Aripiprazole tablet, 10 mg, 30 mg, Placebo tablet |
| Enrollment | 302 |
| Start date | Jul 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jan 20, 2005 |
| Last update posted | Aug 10, 2012 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: